ClinicalTrials.gg
Status unknownNCT02921945Updated Oct 3, 2016

Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A

A Phase 3 interventional study of SCT800 in Hemophilia A, sponsored by Sinocelltech Ltd.. Status unknown at 1 site in China. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-03.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2016), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Planned enrollment
43rd of 80
50 · median 54
Started
2016
with 5 others
Phase 3
41 of 93
9 open now
Registered
17th of 93
by date
Lead sponsor
5 of 93
Sinocelltech Ltd.

Among the 93 studies in Hemophilia A with a site in China, this one is the 43rd largest by planned enrollment of the 80 interventional ones that give a count, is one of 6 that started in 2016, is one of 41 in phase 3, and was the 17th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

In this trial safety and efficacy of SCT800 (B-domain deleted recombinant factor VIII) is being evaluated in 50 subjects, 12 to 65 years of age, with moderate to severe Hemophilia A. These subjects will receive open label treatment with SCT800 for approximately 6 months for on-demand treatment.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 12 to 65 years old;
  • The activity of the coagulation factor VIII (FVIII:C) ≤5%, and was previously treated with FVIII concentrate(s) for a minimum of 50 exposure days (EDs) prior to study entry
  • Bleeding state need to be treated with FVIII;
  • Negative assays for FVIII inhibitors (\<0.6 BU/mL);
  • The count is normal;
  • Normal or INR ≤1.5;
  • Given

Exclusion criteria

Exclusion Criteria:

  • to recombinant coagulation factor VIII concentrate or any of the ;allergic to heterologous proteins (e.g. murine, bovine or hamster origin);
  • Family history or history of FVIII inhibitors (≥0.6 Bethesda Units [BU] mL-1);
  • Received an infusion of any FVIII for on-demand therapy or prophylaxis within 4 days prior to study entry (including rFVIII, plasma-derived factor VIII [pdFVIII], cryoprecipitate and whole blood);
  • Significant hepatic or renal impairment ( and AST ≥2×; BUN and Cr≥2×ULN);
  • seropositive;
  • Abnormal hemostasis from causes other than hemophilia A;
  • Patients with severe heart disease, including myocardial infarction, heart failure (III or higher level);
  • Patients who received any anticoagulant or antiplatelet therapy within one week (including NSAIDs) or need to receive an anticoagulant or antiplatelet therapy during the period of clinical trials;
  • Alcoholism, drug abuse, mental disorders and mental retardation;
  • Elective surgery planned during the process of study;
  • Patients who previously participated in the other clinical trials prior to study entry;
  • The patient or parent/legal guardian is unable or unwilling to sign an form or to comply with the requirements of clinical protocol;
  • Other conditions confirmed by the researchers, resulting in that patients are unable to benefit from clinical observation;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    SCT800

    Biological: SCT800

Interventions

  • BiologicalSCT800

    recombinant human coagulation factor VIII

06

What researchers measure

Primary outcomes

  1. Incremental Recovery (K-value)

    One-stage aPTT Assay

    Time frame: 1hour after the end of the infusion

Secondary outcomes

  1. Haemostatic effect of SCT800 evaluated according to a predefined four grade scale: excellent, good, moderate, or no response

    Time frame: Up to 6 months

  2. The incidence rate of FVIII inhibitors (≥0.6 BU)

    Time frame: Up to 6 months

  3. The number of infusions of SCT800 required per bleeding episode

    Time frame: Up to 6 months

  4. Actual consumption of SCT800 (IU/Kg/bleed)

    Time frame: Up to 6 months

  5. AEs related to SCT800 during the clinical study

    Time frame: Up to 6 months

07

Study locations

1 site
  • Xiangya Hospital of Centre-South University
    Changsha, Hunan 410008, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2016, a primary completion of Dec 2017 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2016
First posted
Oct 3, 2016
Start
Oct 2016
Primary completionEst.
Dec 2017
CompletionEst.
Jun 2018
Last update
Oct 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02921945
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Oct 3, 2016
Start date
Oct 2016
Primary completion
Dec 2017 (estimated)
Completion
Jun 2018 (estimated)
Last update
Oct 3, 2016

Study contacts

Xielan Zhao, PhD
principal investigator · Xiangya Hospital of Centre-South University, Changsha, China

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omfiloctocog alfa

Start the discussion